Acmopatide Reduces A1C and Weight in Type 1 Diabetes Phase 2 Trial
Acmopatide reduces A1C and weight in Type 1 Diabetes Phase 2 Trial, offering potential insulin-sparing benefits in a 16-week...
Immutep’s IMP761 LAG-3 Agonist Meets Safety Goals in Phase I Trial
IMP761 LAG-3 agonist met safety goals in Phase I trial, showing statistically significant T-cell suppression in healthy volunteers at...
FDA Clears IND Amendment for MAIA’s Ateganosine Phase 2 NSCLC Trial Expansion
FDA clears IND amendment for MAIA's ateganosine Phase 2 NSCLC trial expansion, targeting third-line patients with durable survival signals.
Dapirolizumab Pegol Shows Steroid-Sparing Benefit in Phase 3 SLE Trial
Dapirolizumab pegol achieved steroid-sparing benefit in Phase 3 SLE trial, enabling patients to taper glucocorticoids while maintaining disease control.
Zenagamtide achieves 89% A1C target with 14.6% weight loss in diabetes trial
Zenagamtide diabetes trial shows 89% of participants reached A1C targets with 14.6% weight loss in phase 2 study.
TG Therapeutics’ Subcutaneous BRIUMVI Meets Phase 1 Bioavailability Goals
TG Therapeutics' subcutaneous BRIUMVI achieves bioavailability goals in Phase 1, potentially offering quarterly dosing for relapsing multiple sclerosis.
Cabaletta Bio Reports 83% Response Rate for Rese-cel in Dermatomyositis
Cabaletta Bio's rese-cel achieved 83% response rate in dermatomyositis patients, exceeding the 50% threshold needed for regulatory success toward...
Lundbeck’s bocunebart meets primary endpoint in Phase IIb migraine trial
Lundbeck's bocunebart meets primary endpoint in Phase IIb migraine trial, showing 1.38 fewer monthly migraine days versus placebo in...
Cardiff Onvansertib Shows 72% Response Rate in RAS-Mutated Colorectal Cancer
Onvansertib achieved a 72% response rate in RAS-mutated colorectal cancer, prompting Cardiff Oncology to advance to Phase 3 trials.
Kura’s Darlifarnib Shows 67% Response Rate in Pancreatic Cancer Combo Study
Kura's darlifarnib showed a 67% response rate when combined with adagrasib in pancreatic cancer, outperforming historical monotherapy benchmarks.